• Je něco špatně v tomto záznamu ?

Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial

S. Mehta, BK. Sastry, R. Souza, A. Torbicki, HA. Ghofrani, RN. Channick, M. Delcroix, T. Pulido, G. Simonneau, J. Wlodarczyk, LJ. Rubin, P. Jansa, E. Hunsche, N. Galiè, L. Perchenet, O. Sitbon,

. 2017 ; 151 (1) : 106-118. [pub] 20160923

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023677

BACKGROUND: Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated. METHODS: Patients were randomized to placebo, macitentan 3 mg, or macitentan 10 mg once daily. Patients aged 14 years or older completed the 36-Item Short Form Survey (SF-36) at baseline, at month 6 and month 12, and at the end of treatment (EOT). The absolute change from baseline to month 6 in SF-36 scores was calculated. The time to a clinically meaningful deterioration in the SF-36 physical component summary and mental component summary (PCS and MCS) scores and associations between baseline PCS/MCS scores and time to morbidity/mortality events were also assessed. RESULTS: At month 6, macitentan 10 mg significantly improved seven of eight SF-36 domains and the PCS and MCS scores vs placebo. Macitentan 10 mg significantly reduced the risk of a three-point or greater deterioration in PCS (hazard ratio [HR], 0.60; 95% CI, 0.47-0.76; P < .0001) and MCS scores (HR, 0.76; 95% CI, 0.61-0.95; P = .0173) until EOT vs placebo. Patients with a baseline PCS score greater than the median baseline value had a significantly reduced risk of morbidity/mortality compared with patients with a PCS score less than the median; a similar result was observed for the MCS score. CONCLUSIONS: Macitentan significantly improved HRQoL in patients with PAH compared with placebo and significantly reduced the risk of a clinically meaningful HRQoL deterioration. An association between better baseline HRQoL and improved long-term outcomes was shown. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00660179; URL: clinicaltrials.gov.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023677
003      
CZ-PrNML
005      
20170906110231.0
007      
ta
008      
170720s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.chest.2016.08.1473 $2 doi
035    __
$a (PubMed)27671974
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mehta, Sanjay $u London Health Sciences Centre, Victoria Hospital, Western University, London, ON, Canada. Electronic address: sanjay.mehta@lhsc.on.ca.
245    10
$a Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial / $c S. Mehta, BK. Sastry, R. Souza, A. Torbicki, HA. Ghofrani, RN. Channick, M. Delcroix, T. Pulido, G. Simonneau, J. Wlodarczyk, LJ. Rubin, P. Jansa, E. Hunsche, N. Galiè, L. Perchenet, O. Sitbon,
520    9_
$a BACKGROUND: Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated. METHODS: Patients were randomized to placebo, macitentan 3 mg, or macitentan 10 mg once daily. Patients aged 14 years or older completed the 36-Item Short Form Survey (SF-36) at baseline, at month 6 and month 12, and at the end of treatment (EOT). The absolute change from baseline to month 6 in SF-36 scores was calculated. The time to a clinically meaningful deterioration in the SF-36 physical component summary and mental component summary (PCS and MCS) scores and associations between baseline PCS/MCS scores and time to morbidity/mortality events were also assessed. RESULTS: At month 6, macitentan 10 mg significantly improved seven of eight SF-36 domains and the PCS and MCS scores vs placebo. Macitentan 10 mg significantly reduced the risk of a three-point or greater deterioration in PCS (hazard ratio [HR], 0.60; 95% CI, 0.47-0.76; P < .0001) and MCS scores (HR, 0.76; 95% CI, 0.61-0.95; P = .0173) until EOT vs placebo. Patients with a baseline PCS score greater than the median baseline value had a significantly reduced risk of morbidity/mortality compared with patients with a PCS score less than the median; a similar result was observed for the MCS score. CONCLUSIONS: Macitentan significantly improved HRQoL in patients with PAH compared with placebo and significantly reduced the risk of a clinically meaningful HRQoL deterioration. An association between better baseline HRQoL and improved long-term outcomes was shown. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00660179; URL: clinicaltrials.gov.
650    _2
$a dospělí $7 D000328
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a antagonisté endotelinového receptoru B $x aplikace a dávkování $x škodlivé účinky $7 D065131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a plicní hypertenze $x diagnóza $x farmakoterapie $x patofyziologie $x psychologie $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a posouzení stavu pacienta $7 D062072
650    12
$a pyrimidiny $x aplikace a dávkování $x škodlivé účinky $7 D011743
650    12
$a kvalita života $7 D011788
650    12
$a sulfonamidy $x aplikace a dávkování $x škodlivé účinky $7 D013449
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Sastry, Bhagavatula Kutumba Srinivasa $u CARE Hospitals, Hyderabad, India.
700    1_
$a Souza, Rogério $u Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
700    1_
$a Torbicki, Adam $u Centre of Postgraduate Medical Education, Europejskie Centrum Zdrowia, Otwock, Poland.
700    1_
$a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center, Giessen, Germany, Member of the German Center of Lung Research (DZL), Giessen, Germany, and Department of Medicine, Imperial College London, London, England.
700    1_
$a Channick, Richard N $u Massachusetts General Hospital, Boston, MA.
700    1_
$a Delcroix, Marion $u Gasthuisberg University Hospital, Leuven, Belgium.
700    1_
$a Pulido, Tomás $u Ignacio Chávez National Heart Institute, Mexico City, Mexico.
700    1_
$a Simonneau, Gérald $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.
700    1_
$a Wlodarczyk, John $u John Wlodarczyk Consulting Services, Newcastle, Australia.
700    1_
$a Rubin, Lewis J $u University of California, San Diego Medical School, San Diego, CA.
700    1_
$a Jansa, Pavel $u Charles University, Prague, Czech Republic.
700    1_
$a Hunsche, Elke $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Galiè, Nazzareno $u Bologna University Hospital, Bologna, Italy.
700    1_
$a Perchenet, Loïc $u Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
700    1_
$a Sitbon, Olivier $u Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.
773    0_
$w MED00002127 $t Chest $x 1931-3543 $g Roč. 151, č. 1 (2017), s. 106-118
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27671974 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170906110829 $b ABA008
999    __
$a ok $b bmc $g 1239358 $s 984590
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 151 $c 1 $d 106-118 $e 20160923 $i 1931-3543 $m Chest $n Chest $x MED00002127
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace